The Cosmetic Ingredient Review (CIR) reports that Dr. F. Alan Andersen has retired.Dr. Lillian Gill, deputy director, was named as the next director of the CIR, an independent, non-profit panel of scientific and medical experts that assesses the safety of cosmetic ingredients used in the US.
Dr. Andersen joined the US Food and Drug Administration (FDA) in 1971 as a researcher studying the genotoxic effects of radiation after completing his Ph.D. in Biophysics at Penn State. After more than 22 years in numerous leadership roles at the FDA, Dr. Andersen joined the CIR as director. He is a past president of Clinical and Laboratory Standards Institute (CLSI), an organization promoting the development and use of voluntary consensus standards and guidelines for clinical testing. He has served on the Board of Directors of the Penn State Graduate School Alumni Association and as the President of the Food and Drug Administration Alumni Association.
Dr. Lillian Gill has served as deputy director since 2011. Prior to joining the CIR, she served as the senior associate director of the FDA’s Center for Devices and Radiological Health (CDRH) and was a member of the Senior Executive Service.
Dr. Gill served on the Boards of Directors at the American Association of Medical Instrumentation and the CLSI and on the Boards of Examiners for the VA (Robert Carey Performance Excellence Award Program) and the University of Maryland (Maryland Performance Excellence Awards Program).
Dr. Gill also has significant international experience as the Head of Delegation (FDA) for the Memorandum of Agreement with the State FDA of China, and the Head of Delegation (US) for the Global Harmonization Task Force Steering Committee. Dr. Gill’s extensive experience with FDA has also included leadership positions as Acting Director in FDA’s Device Center’s science and engineering laboratories, Director of the Office of Compliance, and in the Office of the Center Director.